These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 9519738)

  • 1. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes.
    Fuhlendorff J; Rorsman P; Kofod H; Brand CL; Rolin B; MacKay P; Shymko R; Carr RD
    Diabetes; 1998 Mar; 47(3):345-51. PubMed ID: 9519738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
    Hu S; Wang S; Fanelli B; Bell PA; Dunning BE; Geisse S; Schmitz R; Boettcher BR
    J Pharmacol Exp Ther; 2000 May; 293(2):444-52. PubMed ID: 10773014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
    Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
    Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
    Malaisse WJ
    Treat Endocrinol; 2003; 2(6):401-14. PubMed ID: 15981944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells.
    Gromada J; Dissing S; Kofod H; Frøkjaer-Jensen J
    Diabetologia; 1995 Sep; 38(9):1025-32. PubMed ID: 8591815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of repaglinide upon nutrient metabolism, biosynthetic activity, cationic fluxes and insulin release in rat pancreatic islets.
    Louchami K; Jijakli H; Sener A; Malaisse WJ
    Res Commun Mol Pathol Pharmacol; 1998 Feb; 99(2):155-68. PubMed ID: 9583090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels.
    Stephan D; Winkler M; Kühner P; Russ U; Quast U
    Diabetologia; 2006 Sep; 49(9):2039-48. PubMed ID: 16865362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide.
    Hu S; Wang S; Dunning BE
    Int J Exp Diabetes Res; 2001; 2(1):63-72. PubMed ID: 12369728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of a new class of insulin secretagogues.
    Malaisse WJ
    Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S140-3. PubMed ID: 10522840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action.
    Hu S
    Eur J Pharmacol; 2002 May; 442(1-2):163-71. PubMed ID: 12020694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic islet responsiveness to D-glucose after repeated administration of repaglinide.
    Laghmich A; Ladrière L; Malaisse-Lagae F; Malaisse WJ
    Eur J Pharmacol; 1998 May; 348(2-3):265-70. PubMed ID: 9652342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repaglinide, glibenclamide and glimepiride administration to normal and hereditarily diabetic rats.
    Ladrière L; Malaisse-Lagae F; Fuhlendorff J; Malaisse WJ
    Eur J Pharmacol; 1997 Sep; 335(2-3):227-34. PubMed ID: 9369378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of insulinotropic agent nateglinide on Kv and Ca(2+) channels in pancreatic beta-cell.
    Hu S; Wang S
    Eur J Pharmacol; 2001 Sep; 427(2):97-104. PubMed ID: 11557260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2].
    Rutten GE
    Ned Tijdschr Geneeskd; 2001 Aug; 145(32):1547-50. PubMed ID: 11525087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulfonylurea induced beta-cell apoptosis in cultured human islets.
    Maedler K; Carr RD; Bosco D; Zuellig RA; Berney T; Donath MY
    J Clin Endocrinol Metab; 2005 Jan; 90(1):501-6. PubMed ID: 15483097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels.
    Hansen AM; Hansen JB; Carr RD; Ashcroft FM; Wahl P
    Br J Pharmacol; 2005 Feb; 144(4):551-7. PubMed ID: 15678092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of K+ channels and stimulation of insulin secretion by the sulfonylurea, glimepiride, in relation to its membrane binding in pancreatic islets.
    Schwanstecher M; Mnner K; Panten U
    Pharmacology; 1994 Aug; 49(2):105-11. PubMed ID: 7972319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of repaglinide on insulin secretion in islets from rats infused for two days with a hypertonic solution of D-glucose.
    Louchami K; Ladrière L; Jijakli H; Malaisse WJ
    Endocrine; 1998 Jun; 8(3):247-50. PubMed ID: 9741829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of the Kir6.2 N-terminus for the interaction of glibenclamide and repaglinide with the pancreatic K(ATP) channel.
    Kühner P; Prager R; Stephan D; Russ U; Winkler M; Ortiz D; Bryan J; Quast U
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Mar; 385(3):299-311. PubMed ID: 22083559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.